VTGN Vistagen Therapeutics, Inc.

VistaGen Therapeutics Inc is a clinical-stage biopharmaceutical company that develops and commercializes product candidates for patients with central nervous system diseases. Its product AV-101 is currently being evaluated in a Phase 2 monotherapy study.

$2.20  -0.10 (-4.35%)
As of 10/27/2021 15:59:43 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  192,903,896
Average volume:  942,767
Market cap:   $435,962,805
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92840H202
ISIN:        US92840H2022
Valuation   (See tab for details)
PE ratio:   -9.45
PB ratio:   5.15
PS ratio:   302.00
Return on equity:   -20.16%
Net income %:   -1,195.52%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy